Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068831 | 0.87 | HCRTR1 (0.49) | HCRTR1HCRTR2LMNAMAPTL3MBTL1 | |
| SCHEMBL3369471 | 0.80 | HCRTR1 (0.54) | HCRTR1HCRTR2L3MBTL1NPC1RAB9A | |
| SCHEMBL3366091 | 0.80 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL3367428 | 0.77 | HCRTR1 (0.55) | HCRTR1HCRTR2NPC1RAB9A | |
| SCHEMBL3370489 | 0.76 | HCRTR1 (0.43) | HCRTR1HCRTR2LMNAMAPTTSHR | |
| SCHEMBL3369395 | 0.76 | HCRTR1 (0.56) | HCRTR1HCRTR2NPC1RAB9A | |
| SCHEMBL3368893 | 0.75 | HCRTR1 (0.62) | HCRTR1HCRTR2 | |
| SCHEMBL3364808 | 0.75 | HCRTR1 (0.49) | HCRTR1HCRTR2L3MBTL1NPC1RAB9A | |
| SCHEMBL3367485 | 0.74 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL3366979 | 0.74 | HCRTR1 (0.51) | HCRTR1HCRTR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105538-B2 | 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | OPRD1, OPRK1, GRIN2C | HCRTR1 461/4885HCRTR2 146/4885ENPP2 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.